View this email in your browser

IowaBio Monthly Newsletter

September 2020



Webinar: Leveraging NCATS SBIR/STTR Funding to Support Innovation in Translational Science
Join IowaBio in collaboration with the NIH National Center for Advancing Translational Sciences (NCATS) for a webinar on small business funding programs on Tuesday, September 22, 2020 at 1:30 – 2:30 p.m. CT.

Lili Portilla, Director of the Office of Strategic Alliances at NCATS, will present an overview of the Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) programs, which offer non-dilutive funding and resources to help small businesses advance and commercialize promising translational biotech and life sciences research technologies. You’ll learn about NCATS’ key research focus areas, tips for submitting a successful application, upcoming funding opportunities and other NCATS resources and programs for researchers and entrepreneurs. You can ask questions during a dedicated Q&A session. 

Register now to join the webinar, Leveraging NCATS SBIR/STTR Funding to Support Innovation in Translational Science, on Tuesday, September 22, 2020 at 1:30 – 2:30 p.m. CT.
Register Today
Thank you to everyone who participated in our (windy!) outing yesterday and thanks again to Fisher Scientific, CRB, BrownWinick Law, and VWR for sponsoring the event! It was great to get out in the sunshine and see some friendly faces (at an appropriate distance).
Brex Corporate Credit Card
Great news! We have added a new partner to our BioVantage Program - Brex Corporate Credit Card. IowaBio members now have access to this exclusive savings opportunity! Brex offers our members an exclusive sign-on bonus and waived card fees for life.

IowaBio Member Benefits:
  • 60,000 point signup bonus ($600 value)
  • Waived card fees for life ($60 p/card p/year)
  • Tailored rewards and points with 3x on lab supplies, 7x on conference registrations, 4x on travel, and 1x on everything else
  • 5-minute application process (completely online) with instant access to virtual cards
  • No personal guarantee or collateral requirements
Want more good news? You do not have to be a life science company to use this card! IowaBio's Support and Institutional members can also use this card and receive the exact same benefits!

Reach out to us with any questions or sign up today!
Sign Up Today
Fisher Scientific Rebate Opportunity
  1. Be an active IowaBio member as of December 31, 2020
  2. Use IowaBio's Fisher Scientific contract before December 1, 2020
  3. Increase your total Fisher catalog spend from the 2019 calendar year
  4. Reach a minimum rebate total of $50

Our members have saved over $80 million 
through our Fisher contract since 2012!

For more information or a price comparison 
on your frequently purchased items, contact 
your Fisher representative or IowaBio.

Reach out to us and we'd be happy to help! Download the rebate flier and share it with your purchasing department today!

Jessica Hyland, Executive Director

Melissa Moyer, Associate Director
Download Rebate Flier
8th: Government Affairs Committee Meeting
2:15 - 4:15pm

17th: Quarterly Board Meeting
9:30 - 11:30am

IowaBio would like the welcome the following new member to our association!

IowaBio thanks the following members for recently renewing:
Gross-Wen Technologies receives an Innovation Acceleration Propel fund from the IEDA Board
An Iowa State University spinoff headquartered in Slater, Gross-Wen Technologies has a patented algae system known as the revolving algal biofilm treatment system marketed under the RABTM brand. The technology enables the effective and sustainable use of algae to remove nitrogen and phosphorous from wastewater. It can also be used with clean water to grow high value algae (“clean algae”) for various uses to include nutraceuticals, human food and animal feeds. Learn more >
AdvaMed Commends CMS Proposed Rule to Improve Coverage For Innovative, “Breakthrough” Technologies
“In order to incentivize innovative medical breakthroughs, the federal government must ensure those breakthrough technologies are covered by Medicare,” said Scott Whitaker, AdvaMed president and CEO. “We are pleased that this proposed rule gets us closer to this goal as it would help ensure the patients who need these innovative technologies have access to them. We thank HHS Secretary Azar and CMS Administrator Verma for their leadership. The Administration’s continued focus on the value of medical technology and innovative breakthroughs will without question help to alleviate human suffering and save lives.” Learn more >
Kemin Industries Acquires U.S. Patent Application for Effective Solution to Control African Swine Fever Virus in Feed
Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services, has acquired a U.S. patent application for a method to control African Swine Fever virus (ASFv) in feed and feed ingredients using Sal CURB® Liquid Antimicrobial – a global pathogen control product manufactured by Kemin. Learn more >
PowerPollen closes $13 million series B
PowerPollen announced the close of its $13 million Series B funding round to accelerate global adoption in corn seed production and expand innovation to corn grain, wheat and rice. The round will expand PowerPollen’s ability to help customers increase yield and enable product innovation across a wider diversity of hybrids by preserving and applying pollen on-demand. New investor Ag Ventures Alliance and several return investors, including Iowa Corn Growers Association, materially participated in the round. Learn more >
Kent Corporation Had a Pandemic Plan Ready to Go
When the COVID-19 pandemic struck the United States, Kent Corporation—an Iowa-based food and beverage manufacturer—was ready. In fact, the company had been ready for 11 years. Back in 2009, Kent Corporation implemented a pandemic response protocol. Prepared by the company’s own human resources group, it was designed to help the company find solutions to novel problems, implement procedures and distribute information internally within the company. Learn more >
Registration is Now Open for the 45th Annual Forum on Science & Technology Policy
2020 marks the 45th anniversary of the AAAS Forum on Science & Technology Policy. We will gather to discuss major current challenges affecting science, policy and society, as well as their intersectionalityLearn more >
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
Pfizer Inc. and BioNTech SE today shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against SARS-CoV-2, which has advanced into Phase 2/3 evaluation. The newly released manuscript describes key safety and immunogenicity data from the U.S. Phase 1 trial for the BNT162b2 vaccine candidate, which at30μg recorded 7 days after the second dose elicited SARS-CoV-2-neutralizing geometric mean titers (GMTs) in younger adults (18-55 years of age) that were 3.8 times the GMT of a panel of 38 sera of SARS-CoV2 convalescent patients, and in older adults (65-85 years of age) the vaccine candidate elicited a neutralizing GMT 1.6 times the GMT of the same panel, demonstrating strong immunogenicity in younger and older adults. Learn more >

The Session Bill Tracker is a weekly report issued every Friday during legislative session. It provides an update on state and federal activities as well as a tracking record of bills relevant to the biotech industry and IowaBio’s position. This report is best suited for government affairs representatives and biotech companies engaged in policy efforts. To view archives of this distribution of sign up for the communications, please click here.

Our Monthly Newsletter is a great resource to keep up with IowaBio's activities, member and industry news, as well as additional savings, educational and networking opportunities in your area and across the globe. To view archives of this distribution or sign up for the newsletter, please click here

Starting March 23rd, IowaBio began issuing daily updates to share the latest news surrounding the virus from the biotech industry's point of view. Topics covered include state, national and global updates, legislative activities on the state and federal level, IowaBio member efforts and innovations, helpful resources/media and more.

If you are an IowaBio member and wish to receive this daily communication, please email Melissa Moyer at Non-members can access the communications once they've been issued on our archives page.
Copyright © 2019 Iowa Biotechnology Association, All rights reserved.

Our mailing address is:
500 E Court Avenue, Suite 112
Des Moines, IA 50309-2057

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.